Introduction of the speakers
Dr. Krishna Allamneni is the Chief Development Officer & Executive Vice President at Concarlo Therapeutics and Senior Advisor at Ventures Accelerated AB.
With 25+ years of experience in biopharmaceutical leadership, Dr. Allamneni specializes in early drug development and corporate strategy, guiding therapeutics from discovery to commercialization across multiple therapeutic areas and modalities.
Dr. Erik Hemberg is a research scientist at MIT CSAIL specializing in artificial intelligence and data-driven methods across life sciences, cybersecurity, and complex systems. With over 15 years of experience in AI, machine learning, and data science, his work bridges cutting-edge computational techniques with real-world applications in neuroscience, learning systems, and biomedical and security domains.
He has collaborated with leading organizations including OpenAI, MIT-IBM AI Alliance, DARPA, MIT Lincoln Laboratory, and U.S. government agencies, securing competitive research funding for interdisciplinary AI initiatives.
Marek Szczygiel leads Anyo Labs, combining his medical background with a strong focus on technology and innovation. Educated at Poznan University of Medical Sciences and Chalmers University of Technology, he combines clinical expertise with entrepreneurial strategy.
At Anyo Labs, he uses AI and advanced computational modeling to help pharma and biotech companies identify and optimize promising drug candidates earlier in development, accelerating timelines and reducing reliance on traditional lab work.
Wing Cheng is Senior Business Developer in Life Science at Uppsala Innovation Centre (UIC) and board professional in life science start-ups.
Wing works closely with emerging companies at UIC and serves as chairman of LanteRNA, while also mentoring entrepreneurs through the Nordic Mentor Network for Entrepreneurship.
His background includes leadership roles at Immuneed, Biovica, Thermo Fisher Scientific, and Cepheid, as well as regulatory work at the Swedish Medical Products Agency and TLV.
Martin Kjellberg is a PhD Student in Genetics at Stanford University. His research sits at the intersection of AI and genomics, using machine learning and multi-omics data to advance precision medicine.
With a background in Medical Biotechnology from KTH, Martin develops deep learning methods to analyze whole-genome sequencing and uncover genetic drivers of complex diseases.